Compare AbCellera Biologics Inc (ABCL) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs PulteGroup, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while PulteGroup, Inc. trades at $123.51 (market cap $24.75B). The key difference: PulteGroup, Inc. is far larger — about 10.5× AbCellera Biologics Inc's market cap, and PulteGroup, Inc. pays a 0.8% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PHM | |
|---|---|---|
Market Cap | $2.35B | $24.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $142.56 |
52-Week Low | $2.78 | $108.00 |
Enterprise Value | $1.99B | $24.71B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
PulteGroup (PHM) trades at $129.92, down 2.81% on the day, amid mixed earnings performance with recent quarterly misses. The stock shows a bullish technical signal with strong moving averages and oversold RSI levels, while fundamentals reflect solid profitability with a 12.14% net margin and attractive valuation at a P/E of 12.71. Recent corporate developments include land acquisition for a new community, signaling growth initiatives.
The outlook is cautiously optimistic, supported by analyst consensus and a $144.17 price target, but risks include margin pressure from incentives and housing market sensitivity to interest rates. Investment appeal hinges on execution of margin recovery and sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
